Claims 1-3, 5-21, 24 and 30-32 were rejected under 35 USC 102(e) as being anticipated over Matyjaszewski et al. Matyjaszewski et al do not anticipate the present invention.

The process of the instant invention as recited in claim 33 comprises adding an alkenyl-containing polymer (I) to a living radical polymerization system or a living cationic polymerization system.

On the other hand, Matyjaszewski et al do not disclose a process that comprises adding an alkenyl-containing polymer (I) to a living radical polymerization system or a living cationic polymerization system.

Thus, col. 5, lines 24-27 of Matyjaszewski et al fails to teach the addition of an alkenyl-containing polymer. In addition, both col. 22, scheme 5 and col. 22, Example "d" suggest the radical polymerization reaction comprising the addition of a halogenterminated monomer as an initiator, but none of them teaches the addition of an alkenyl-containing polymer.

Therefore, the process of Matyjaszewski et al does not constitute the process of the invention.

Consequently, the present invention is novel.

The present invention provides a process capable of producing block copolymers having various alkenyl-containing polymers by adding those various polymers to a living radical polymerization system or a living cationic polymerization system (page 69, line 26 – page 70, line 5). On the other hand, the cited reference cannot provide such block copolymers attainable by the process of the invention.

Consequently, the present invention would not have been obvious based on the suggestions of Matyjaszewski et al.

Matyjaszewski et al do not anticipate the present invention. In particular, anticipation requires the disclosure, in a prior art reference, of each and every recitation as set forth in the claims. See *Titanium Metals Corp. v. Banner*, 227 USPQ 773 (Fed. Cir. 1985), *Orthokinetics, Inc. v. Safety Travel Chairs, Inc.*, 1 USPQ2d 1081 (Fed. Cir.

1986), and Akzo N.V. v. U.S. International Trade Commissioner, 1 USPQ2d 1241 (Fed. Cir. 1986).

There must be no difference between the claimed invention and reference disclosure for an anticipation rejection under 35 USC 102. See *Scripps Clinic and Research Foundation v. Genentech, Inc.*, 18 USPQ2d 1001 (CAFC 1991) and *Studiengesellschaft Kohle GmbH v. Dart Industries*, 220 USPQ 841 (CAFC 1984).

In view of the above, consideration and allowance are, therefore, respectfully solicited.

In the event the Examiner believes an interview might serve to advance the prosecution of this application in any way, the undersigned attorney is available at the telephone number noted below.

The Director is hereby authorized to charge any fees, or credit any overpayment, associated with this communication, including any extension fees, to CBLH Deposit Account No. 22-0185.

Respectfully submitted,

Burton A. Amernick (24,852)

Customer Number 30678

Connolly Bove Lodge & Hutz LLP

1990 M Street, N.W.

Washington, D.C. 20036-3425

Telephone: 202-331-7111

Date: 1-2-02